April 14, 2025

Pfizer Halts Danuglipron Obesity Pill Trials

Pfizer discontinues development of potential weight-loss drug due to liver injury in trial participant, impacting stock prices and future strategies.

Reuters

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 02, 2025

GLP-1 Spending Surged 500% Since 2018

U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 27, 2025

Simplified Tesamorelin Option for HIV Lipodystrophy

EGRIFTA WR™ has received FDA approval for use in adults with HIV and lipodystrophy to reduce excess abdominal fat with once-weekly reconstitution and a lower injection volume.

Conexiant

March 21, 2025

Contaminant Limits Now Searchable, Says FDA

New online tool lists chemical levels in human foods as part of broader federal push to improve transparency and reduce harmful additives.

Reuters

March 19, 2025

Study Shows Widespread Delays in Medical Device Reporting to FDA

Late reporting was concentrated among a small number of manufacturers, with 3 manufacturers and 13 devices accounting for 54.8% of all late reports between 2019 and 2022.

Conexiant